CD8A and neoplasm: Herein we present the potential of targeting YY1, since it directly inhibits the expression of more than one inhibitory receptor on the CD8 T cells and thereby prevents the inactivation of CD8 T cells by the ligands bearing tumor cells, preventing cancer immune evasion.